She added that HER2-positive solid tumors are rare in some cancer types, such as ovarian and endometrial cancers. Because of rarity, many HER2-positive solid tumor subtypes did not have any ...

Radiopharm Presents Positive RAD202 Data For HER2-Positive Solid Tumors At EMIM 2025 March 17, 2025 — 11:05 am EDT Written by RTTNews.com for RTTNews -> ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor.

Triumvira Immunologics Presents Initial HER2-Positive Solid Tumor Clinical Data at ESMO. Early signals of clinical activity observed in second dosing cohort with one partial response.

Cite this: FDA Expands Enhertu Indication to HER2-Positive Solid Tumors - Medscape - April 08, 2024. Comments . Commenting is limited to medical professionals. To comment please .

This is the first “tumor agnostic” approval for HER2-positive solid tumors defined as having strong immunohistochemistry HER2 staining of three plus, “which is really exciting,” she said. Sammons is a ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.

The study population included 192 adults with previously treated unresectable or metastatic HER2-positive (IHC3+) solid tumors. The primary endpoint was confirmed objective response rate (ORR).

“Until the approval of trastuzumab deruxtecan, patients with metastatic HER2 positive solid tumors have had limited treatment options,” Funda Meric-Bernstam, MD, chair of Investigational ...

Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis If approved ...

Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program. ... is looking at ELVN-002 in combination with Roche’s Herceptin for patients with HER2-positive colorectal cancer.